Relentless pursuit of improved patient outcomes

Opened new laboratory in Pittsburgh, doubling footprint of prior facility

Acquisition of AltheaDx and the IDgenetix® test

Acquisition of Cernostics and the TissueCypher® Barrett’s Esophagus test

Acquisition of the MyPath® Melanoma laboratory and MyPath Melanoma test

New corporate headquarters in Friendswood, TX

Introduction of DiffDx®-Melanoma

Introduction of DecisionDx®-SCC

Doubled footprint of Phoenix laboratory

First two meta-analyses published for DecisionDx®-Melanoma

Initial public offering completed

Formal Medicare Local Coverage Determination (LCD) for DecisionDx®-Melanoma

DecisionDx®-UM included in National Comprehensive Cancer Network (NCCN) guidelines

Formal Medicare Local Coverage Determination (LCD) for DecisionDx®-UM

Introduction of DecisionDx®-Melanoma

DecisionDx®-UM included in AJCC guidelines

Introduction of DecisionDx®-UM

Began operations